https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-11 07:10:272026-06-11 08:37:50Poolbeg Pharma announces successful site activation for POLB 001 TOPICAL clinical trial
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-11 07:10:272026-06-11 08:37:50Poolbeg Pharma announces successful site activation for POLB 001 TOPICAL clinical trial
Hansa Biopharma appoints Fredrik Röök as VP Business Development
Lund, Sweden, 10 June 2026. Hansa Biopharma AB, “Hansa” (Nasdaq…

CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome
Builds on positive Phase I safety data and represents a key…

Sofinnova Partners launches collaboration with AWS to scale AI across life sciences innovation
Sofinnova combines its sector expertise with AWS’s AI and…

DaltonTx launches its drug discovery platform, Dalton, and announces Sygnature Discovery collaboration
Dalton is a drug discovery platform integrating agentic AI,…

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development
Oversubscribed Series B financing co-led by new investors…

Hansa Biopharma participating in Jefferies Global Healthcare Conference in New York
Lund, Sweden, June 2, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq…

FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
Exceptional track record across multiple clinical development…

Hansa Biopharma’s CEO Renée Aguiar-Lucander named one of Sweden’s Most Influential Business Women of 2026
Lund, Sweden, 29 May 2026. Hansa Biopharma AB, “Hansa” (Nasdaq…

Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation
Study to evaluate the safety and exploratory efficacy of…

ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics
Commercial-scale production of Kaleido consumables begins…

Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
The 1-year graft failure-free survival was 90%, which is…

Bonito Biosciences and DaltonTx Announce AI-Driven Collaboration to Advance Precision Delivery for Oligotherapeutics
Collaboration combines Bonito’s proprietary functional…

Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
Lund, Sweden, May 25, 2026. Hansa Biopharma AB, “Hansa”…

Poolbeg Pharma plc – pre-IND meeting with the FDA for POLB 001
FDA feedback supports Poolbeg's proposed development pathway…

Resolution Therapeutics congratulates University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis
Results support progression of EMERALD clinical trial of Resolution’s…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York